Clinical Trial Update: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy [Phase 3]

View source ↗

Summary

Phase 3 study comparing VRd induction followed by cilta-cabtagene autoleucel (cilta-cel) CAR-T therapy versus Rd therapy in newly diagnosed multiple myeloma pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carvykti (cilta-cabtagene autoleucel) (cilta-cabtagene autoleucel)
• DEXAMETHASONE (Dexamethasone)
• Revlimid (lenalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING